ASCO 2024 | A network meta-analysis comparing the efficacy of covalent BTK inhibitors in R/R CLL
Mazyar Shadman, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, discusses the findings of a network meta-analysis comparing the efficacy of covalent BTK inhibitors (BTKi) ibrutinib, zanubrutinib, and acalabrutinib for treating relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Dr Shadman highlights some significant differences between the agents regarding response and survival outcomes, emphasizing that this indirect comparison cannot replace a gold-standard direct comparison using a randomized clinical trial. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
